知識社群
登入
中文(台灣)
English(US)
Q&A
線上人數:
264
MODERN RADIOTHERAPY AND THERAPEUTIC RADIOLOGICAL PHYSICS
相簿輪播 - Welcome Address
社群功能
Home page
Documents
(15)
Calendar
Photo Album
(4)
文件分類
[
總覽
]
Sri Lanka WS
(15)
Vietnam WS
社群資訊
訪客: 70997
文章: 15
討論: 0
公告: 2
容量: 剩餘
1.4 GB
(1.9 GB)
閱讀權限: 開放
分類:
醫療保健 / 醫學新知
版主: tcc
副版主: 無
位置:
MODERN RADIOTHERAPY AND THERAPEUTIC RADIOLOGICAL PHYSICS
>
Documents
>
Sri Lanka WS
Physicians Perspective II : Lung Cancer
(40:20)
Tweet
by tcc, 2011-04-19 20:55, 人氣(5102)
嵌入
|
cc Media
|
轉檔資訊
更清晰的畫質或聲音，請點選(限 IE)
標題
1.
New Radiation Therapy Approaches for Non-Small Cell Lung Cancer
2.
The Global Burden of Cancer
3.
Cancer Mortality Rates for Men
4.
Cancer Rates in Sri Lanka
5.
Worldwide Cancer Incidence and Mortality by Organ Site
6.
Lung CancerCommon and Usually Fatal
7.
Slide 7
8.
How Big Is the Problem?
9.
Worldwide Changes in Lung Cancer Incidence
10.
Cancer Control Issues
11.
NLST Screening Trial
12.
Slide 12
13.
Slide 13
14.
Slide 14
15.
Complexities of Lung Carcinogenesis
16.
Change in Histology
17.
Lung Cancer in Never Smokers
18.
NSALC Is a Common Disease
19.
Possible Causes of Lung Cancer in Never Smokers
20.
Genetic Differences Between Lung Cancer in Smokers and Never Smokers
21.
Molecular Profiling of Lung Adenocarcinoma
22.
Slide 22
23.
EGFR Activating Mutations
24.
Slide 24
25.
EGFR Signaling as a Prototype for Individualized Targeted Therapy
26.
Slide 26
27.
Waterfall Plot for Response to Crizotinib
28.
Slide 28
29.
Therapy Has Changed in the Past 30 Years
30.
Slide 30
31.
Radiation Oncology Issues in Lung Cancer - 2011
32.
CT/PET Treatment Planning
33.
CT/PET Treatment Planning
34.
CT/PET Treatment Planning
35.
Concurrent Therapy is Better
36.
Should We Omit Elective Nodal Irradiation?
37.
Phase III Trial of Target Volume and Dose
38.
Lung V20
39.
Overall Survival
40.
Questions about ENI
41.
Why Do We Still Use 60 Gy to Treat NSCLC?
42.
RTOG 0617
43.
Combining EGFR Targeted Agents with TRT for NSCLC
44.
Bonner Trial Outcomes
45.
RTOG 0617Radiation Planning Issues
46.
Adjuvant Mediastinal Irradiation In Patients With Resected N2 NSCLC
47.
Slide 47
48.
Slide 48
49.
SEER DataNon-Randomized
50.
ANITA Trial RT EffectNon-randomized
51.
ACOSOG/RTOG Trial Patient Flow
52.
A Tentative Nodal Policy
53.
Definitive Radiotherapy for Stage I NSCLC
54.
Node Negative Lung Cancer Gold Standard Rx = Surgery
55.
3-5 Year Survival in Early Stage Lung Cancer
56.
Local Control (LC) in Lung Cancer
57.
SBRT vs. Conventional Radiotherapy
58.
Image Guidance Options
59.
Phase I Dose Response for Local Control
60.
Local Control with Lung SBRT
61.
Grade 3-5 Toxicity vs LocationUsing 18-20 Gyx3 Fractionation
62.
Slide 62
63.
RTOG 0236
64.
Slide 64
65.
Japanese Pooled Retrospective Experience with SBRT in OPERABLE Patients
66.
Lung Cancer Study GroupGinsberg, et al.
67.
Slide 67
68.
Slide 68
69.
Slide 69
70.
Legitimate Alternative to Lobectomy for Stage I NSCLC
71.
Conclusions
72.
Thank you!
... [more]
© 2010 FormosaSoft Corp.
http://www.powercam.com.tw
service@powercam.com.tw
All rights reserved.
